Shilpa Gupta, MD
Hematology & Oncology · Minneapolis, MNNPI 1548455355
Payments from drug & device makers
Across 1,178 payments — averaging $13,811 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$6.5M
- Novartis$3.4M
- Merck$2.8M
- Pfizer$816K
- Genentech, Inc.$634K
- Exelixis Inc.$545K
- plus $1.6M from 27 others
Across 24 payments — averaging $1280.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$21K
- Novartis$6K
- F. Hoffmann-la Roche AG$2K
- Novartis Pharma AG$609
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 304 | $6,463,225 |
| Novartis | 15 | $3,412,929 |
| Merck | 190 | $2,813,642 |
| Pfizer | 77 | $815,556 |
| Genentech, Inc. | 38 | $633,577 |
| Exelixis Inc. | 246 | $545,256 |
| E.r. Squibb & Sons, L.L.C. | 68 | $500,588 |
| Roche Products Limited | 30 | $312,031 |
| Siemens Medical Solutions USA, Inc. | 2 | $204,981 |
| AstraZeneca | 29 | $109,214 |
| Amgen | 1 | $83,091 |
| Astellas Pharma Global Development | 2 | $73,648 |
| Modernatx, Inc. | 15 | $62,686 |
| Gilead | 30 | $60,412 |
| EMD Serono, Inc. | 38 | $59,986 |
| Johnson & Johnson | 24 | $30,234 |
| Astellas Pharma Europe Ltd | 17 | $27,812 |
| Incyte Corporation | 11 | $21,245 |
| Janssen Research & Development, LLC | 5 | $11,561 |
| Janssen Scientific Affairs, LLC | 4 | $5,420 |
| Foundation Medicine, Inc. | 1 | $3,893 |
| Bayer | 1 | $3,425 |
| AVEO Pharmaceuticals, Inc. | 5 | $3,237 |
| Astellas Pharma US Inc | 5 | $2,851 |
| Sanofi | 5 | $2,678 |
| Janssen Global Services, LLC | 3 | $2,328 |
| F. Hoffmann-la Roche AG | 3 | $1,682 |
| Eli Lilly | 3 | $1,505 |
| Genentech USA, Inc. | 2 | $162 |
| EMD Serono Research & Development Institute, Inc. | 1 | $112 |
| Urogen Pharma, Inc. | 1 | $36 |
| Telix Pharmaceuticals | 1 | $24 |
| Genmab U.S., Inc. | 1 | $16 |
How this compares
$16,269,042 in reported general payments places this provider in the 95th percentile of 193 hematology & oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Minneapolis
- Timothy LarsonMinneapolis$7.2M
- Samith KochuparambilMinneapolis$3.3M
- Veronika BachanovaMinneapolis$2.6M
- Douglas YeeMinneapolis$2.6M
- Amit KulkarniMinneapolis$2.5M
- Nicholas ZorkoMinneapolis$2.5M
- Arpit RaoMinneapolis$1.6M
- Daniel OlearyMinneapolis$1.5M
- Mark RedingMinneapolis$1.3M
- Gautam JhaMinneapolis$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.